<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Dr. Reddy's Laboratories Limited — News on 6ix</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited</link>
<description>Latest news and press releases for Dr. Reddy's Laboratories Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 18:39:59 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/dr-reddys-laboratories-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68364bcf78dffbe2df153758.webp</url>
<title>Dr. Reddy's Laboratories Limited</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited</link>
</image>
<item>
<title>Press Release Apr 24 2026</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-apr-24-2026-10</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-apr-24-2026-10</guid>
<pubDate>Fri, 24 Apr 2026 18:39:59 GMT</pubDate>
<description>Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated April 24, 2026, titled "Intimation of Earnings call".</description>
</item>
<item>
<title>Press Release Mar 21 2026</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-mar-21-2026-2</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-mar-21-2026-2</guid>
<pubDate>Sat, 21 Mar 2026 17:59:55 GMT</pubDate>
<description>Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Dr. Reddy s Laboratories announces launch of India s first DCGI-approved Semaglutide injection Obeda® for Type 2 Diabetes.".</description>
</item>
<item>
<title>Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/dr-reddys-announces-usfda-acceptance-to-review-its-biologics-license-application-bla-for-proposed-interchangeable-biosimilar-abatacept</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/dr-reddys-announces-usfda-acceptance-to-review-its-biologics-license-application-bla-for-proposed-interchangeable-biosimilar-abatacept</guid>
<pubDate>Fri, 20 Feb 2026 15:57:00 GMT</pubDate>
<description>HYDERABAD, India, February 20, 2026--Dr. Reddy’s announces USFDA acceptance to review its Biologics License Application (BLA) for proposed interchangeable biosimilar, Abatacept.</description>
</item>
<item>
<title>Press Release Feb 18 2026</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-feb-18-2026-2</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-feb-18-2026-2</guid>
<pubDate>Thu, 19 Feb 2026 00:45:48 GMT</pubDate>
<description>Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated February 18, 2026, titled "Dr. Reddy's forays into Hormone Replacement Therapy segment with acquisition of Progynova® and Cyclo- Progynova® in India".</description>
</item>
<item>
<title>Press Release Jan 14 2026</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-jan-14-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-jan-14-2026-1</guid>
<pubDate>Wed, 14 Jan 2026 21:44:04 GMT</pubDate>
<description>Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated January 14, 2026, titled "Dr. Reddy s announces the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the generic equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.".</description>
</item>
<item>
<title>Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/dr-reddy-announces-first-market-134900905</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/dr-reddy-announces-first-market-134900905</guid>
<pubDate>Wed, 14 Jan 2026 13:49:00 GMT</pubDate>
<description>HYDERABAD, India & PRINCETON, N.J., January 14, 2026--Dr. Reddy’s launched Olopatadine Hydrochloride Ophthalmic Solution USP 0.7% (OTC), a generic equivalent of Extra-Strength Pataday® Once Daily Relief.</description>
</item>
<item>
<title>Press Release Jan 08 2026</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-jan-08-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-jan-08-2026-1</guid>
<pubDate>Thu, 08 Jan 2026 20:44:06 GMT</pubDate>
<description>Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated January 08, 2026, titled "Intimation of Earnings call".</description>
</item>
<item>
<title>Press Release Dec 12 2025</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-dec-12-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-dec-12-2025-1</guid>
<pubDate>Fri, 12 Dec 2025 13:35:38 GMT</pubDate>
<description>Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated December 12, 2025, titled "Dr. Reddy s Laboratories announces Science-Based Net Zero Climate Targets".</description>
</item>
<item>
<title>Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/immutep-and-dr-reddys-enters-into-strategic-collaboration-for-commercialisation-of-an-innovative-oncology-drug-eftilagimod-alfa</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/immutep-and-dr-reddys-enters-into-strategic-collaboration-for-commercialisation-of-an-innovative-oncology-drug-eftilagimod-alfa</guid>
<pubDate>Mon, 08 Dec 2025 13:00:00 GMT</pubDate>
<description>Dr. Reddy’s receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront payment of USD 20 million (~AUD 30.2 million) and is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million (~AUD 528.4 million), plus double-digit royalties on commercial sales Sydney, Australia/Hyderabad, India, Dec. 08, 2025 (GLOBE</description>
</item>
<item>
<title>Press Release Nov 24 2025</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-nov-24-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-nov-24-2025-1</guid>
<pubDate>Mon, 24 Nov 2025 20:48:12 GMT</pubDate>
<description>Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated November 24, 2025, titled "Dr. Reddy s receives European Commission approval for AVT03 (denosumab), a proposed Biosimilar of Prolia® and Xgeva®".</description>
</item>
<item>
<title>Press Release Oct 13 2025</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-oct-13-2025-2</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-oct-13-2025-2</guid>
<pubDate>Mon, 13 Oct 2025 18:53:49 GMT</pubDate>
<description>Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated October 13, 2025, titled "Initmation of Earnings call".</description>
</item>
<item>
<title>Press Release Sep 16 2025</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-sep-16-2025-2</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-sep-16-2025-2</guid>
<pubDate>Tue, 16 Sep 2025 21:13:38 GMT</pubDate>
<description>Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated September 16, 2025, titled "Dr. Reddy's launches novel molecule Tegoprazan in India".</description>
</item>
<item>
<title>Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/extrovis-ag-and-dr-reddys-announce-the-launch-of-the-authorized-generic-of-carac-fluorouracil-cream-05percent-in-the-us</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/extrovis-ag-and-dr-reddys-announce-the-launch-of-the-authorized-generic-of-carac-fluorouracil-cream-05percent-in-the-us</guid>
<pubDate>Mon, 18 Aug 2025 12:16:00 GMT</pubDate>
<description>CARAC (fluorouracil cream), 0.5% . Extrovis AGBahnhof Park 46340, Baar, SwitzerlandMedia Relations ContactMadhu [email protected] Press Release Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. Baar, Switzerland; August 14, 2025 Extrovis AG, a global pharmaceutical company focused on research-driven innovation, and Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with i</description>
</item>
<item>
<title>Press Release Jul 23 2025</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-jul-23-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-jul-23-2025-1</guid>
<pubDate>Wed, 23 Jul 2025 20:48:56 GMT</pubDate>
<description>Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated July 23, 2025, titled "Dr. Reddy s announces its intention to appoint M/s. DeloitteHaskins & Sells LLP as Statutory Auditors effective from FY 2026-27".</description>
</item>
<item>
<title>Dr. Reddy’s Q1FY26 Financial Results</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/dr-reddys-q1fy26-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/dr-reddys-q1fy26-financial-results</guid>
<pubDate>Wed, 23 Jul 2025 17:46:00 GMT</pubDate>
<description>HYDERABAD, India, July 23, 2025--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2025.</description>
</item>
<item>
<title>Cenra Healthcare and Dr. Reddy's Strengthen Strategic Partnership to Expand Access to Medicines in Taiwan</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/cenra-healthcare-and-dr-reddys-strengthen-strategic-partnership-to-expand-access-to-medicines-in-taiwan</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/cenra-healthcare-and-dr-reddys-strengthen-strategic-partnership-to-expand-access-to-medicines-in-taiwan</guid>
<pubDate>Mon, 21 Jul 2025 11:35:00 GMT</pubDate>
<description>Cenra Healthcare, the sales and marketing arm of Cenra Inc. (TWSE: 3716), today announced the deepening of its long-standing collaboration with the global pharmaceutical company Dr. Reddy's Laboratories (Taiwan) Ltd (Dr. Reddy's). Since the partnership began in 2020, the two companies have worked closely to introduce a diverse range of high-quality generic drugs and innovative formulations to patients in Taiwan, with a shared commitment to broadening access to affordable and clinically valuable</description>
</item>
<item>
<title>Press Release Jul 15 2025</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-jul-15-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-jul-15-2025-1</guid>
<pubDate>Tue, 15 Jul 2025 19:16:29 GMT</pubDate>
<description>Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated July 15, 2025, titled "Intimation of Earnings call".</description>
</item>
<item>
<title>Press Release Jun 05 2025</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-jun-05-2025</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/press-release-jun-05-2025</guid>
<pubDate>Thu, 05 Jun 2025 12:40:12 GMT</pubDate>
<description>Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated Jun 05, 2025, titled "Alvotech and Dr. Reddy s enter into Collaboration toCo-Develop Biosimilar Candidate to Keytruda� (pembrolizumab) for global markets.".</description>
</item>
<item>
<title>Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/alvotech-and-dr-reddys-enter-into-collaboration-to-co-develop-biosimilar-candidate-to-keytrudar-pembrolizumab</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/alvotech-and-dr-reddys-enter-into-collaboration-to-co-develop-biosimilar-candidate-to-keytrudar-pembrolizumab</guid>
<pubDate>Thu, 05 Jun 2025 11:00:00 GMT</pubDate>
<description>HYDERABAD, India & REYKJAVIK, Iceland, June 05, 2025--Alvotech and Dr. Reddy’s Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).</description>
</item>
<item>
<title>Dr. Reddy’s Q4 & Full Year FY25 Financial Results</title>
<link>https://6ix.com/company/dr-reddys-laboratories-limited/news/dr-reddys-q4-and-full-year-fy25-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/dr-reddys-laboratories-limited/news/dr-reddys-q4-and-full-year-fy25-financial-results</guid>
<pubDate>Fri, 09 May 2025 18:53:00 GMT</pubDate>
<description>HYDERABAD, India, May 09, 2025--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and year ended March 31, 2025.</description>
</item>
</channel>
</rss>